The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke
Open Access
- 17 June 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Trials
- Vol. 9 (1), 37
- https://doi.org/10.1186/1745-6215-9-37
Abstract
Intravenous recombinant tissue plasminogen activator (rt-PA) is approved for use in selected patients with ischaemic stroke within 3 hours of symptom onset. IST-3 seeks to determine whether a wider range of patients may benefit. International, multi-centre, prospective, randomized, open, blinded endpoint (PROBE) trial of intravenous rt-PA in acute ischaemic stroke. Suitable patients must be assessed and able to start treatment within 6 hours of developing symptoms, and brain imaging must have excluded intracerebral haemorrhage. With 1000 patients, the trial can detect a 7% absolute difference in the primary outcome. With3500 patients, it can detect a 4.0% absolute benefit & with 6000, (mostly treated between 3 & 6 hours), it can detect a 3% benefit. Patients are entered into the trial by telephoning a fast, secure computerised central randomisation system or via a secure web interface. Repeat brain imaging must be performed at 24–48 hours. The scans are reviewed 'blind' by expert readers. The primary measure of outcome is the proportion of patients alive and independent (Modified Rankin 0–2) at six months (assessed via a postal questionnaire mailed directly to the patient). Secondary outcomes include: events within 7 days (death, recurrent stroke, symptomatic intracranial haemorrhage), outcome at six months (death, functional status, EuroQol). ISRCTN25765518Keywords
This publication has 46 references indexed in Scilit:
- Guidelines for the Early Management of Patients With Ischemic StrokeStroke, 2003
- Predicting Outcome After Acute and Subacute StrokeStroke, 2002
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Treatment With Tissue Plasminogen Activator and Inpatient Mortality Rates for Patients With Ischemic Stroke Treated in Community HospitalsStroke, 2001
- A Modified National Institutes of Health Stroke Scale for Use in Stroke Clinical TrialsStroke, 2001
- Utilization of Intravenous Tissue-Type Plasminogen Activator for Ischemic Stroke at Academic Medical CentersStroke, 2001
- Indications for Early Aspirin Use in Acute Ischemic StrokeStroke, 2000
- Tissue Plasminogen Activator for Acute Ischemic StrokeThe New England Journal of Medicine, 1995
- Classification and natural history of clinically identifiable subtypes of cerebral infarctionThe Lancet, 1991
- Interobserver agreement for the assessment of handicap in stroke patients.Stroke, 1989